Skip to main content

In PCI-treated ACS, switching from aspirin + a newer P2Y12 blocker to aspirin + clopidogrel reduced adverse events.

Publication ,  Journal Article
Lowenstern, A; Newby, LK
Published in: Ann Intern Med
September 19, 2017

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Ann Intern Med

DOI

EISSN

1539-3704

Publication Date

September 19, 2017

Volume

167

Issue

6

Start / End Page

JC28

Location

United States

Related Subject Headings

  • Ticlopidine
  • Platelet Aggregation Inhibitors
  • Humans
  • General & Internal Medicine
  • Clopidogrel
  • Aspirin
  • Acute Coronary Syndrome
  • 3202 Clinical sciences
  • 11 Medical and Health Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Lowenstern, A., & Newby, L. K. (2017). In PCI-treated ACS, switching from aspirin + a newer P2Y12 blocker to aspirin + clopidogrel reduced adverse events. Ann Intern Med, 167(6), JC28. https://doi.org/10.7326/ACPJC-2017-167-6-028
Lowenstern, Angela, and L Kristin Newby. “In PCI-treated ACS, switching from aspirin + a newer P2Y12 blocker to aspirin + clopidogrel reduced adverse events.Ann Intern Med 167, no. 6 (September 19, 2017): JC28. https://doi.org/10.7326/ACPJC-2017-167-6-028.
Lowenstern, Angela, and L. Kristin Newby. “In PCI-treated ACS, switching from aspirin + a newer P2Y12 blocker to aspirin + clopidogrel reduced adverse events.Ann Intern Med, vol. 167, no. 6, Sept. 2017, p. JC28. Pubmed, doi:10.7326/ACPJC-2017-167-6-028.

Published In

Ann Intern Med

DOI

EISSN

1539-3704

Publication Date

September 19, 2017

Volume

167

Issue

6

Start / End Page

JC28

Location

United States

Related Subject Headings

  • Ticlopidine
  • Platelet Aggregation Inhibitors
  • Humans
  • General & Internal Medicine
  • Clopidogrel
  • Aspirin
  • Acute Coronary Syndrome
  • 3202 Clinical sciences
  • 11 Medical and Health Sciences